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A bioinspired peptide scaffold with 
high antibiotic activity and low in 
vivo toxicity
Francesc Rabanal1, Ariadna Grau-Campistany1, Xavier Vila-Farrés4, Javier Gonzalez-Linares5, 
Miquel Borràs5, Jordi Vila4, Angeles Manresa3 & Yolanda Cajal2
Bacterial resistance to almost all available antibiotics is an important public health issue. A major 
goal in antimicrobial drug discovery is the generation of new chemicals capable of killing pathogens 
with high selectivity, particularly multi-drug-resistant ones. Here we report the design, preparation 
and activity of new compounds based on a tunable, chemically accessible and upscalable lipopeptide 
scaffold amenable to suitable hit-to-lead development. Such compounds could become therapeutic 
candidates and future antibiotics available on the market. The compounds are cyclic, contain two 
D-amino acids for in vivo stability and their structures are reminiscent of other cyclic disulfide-
containing peptides available on the market. The optimized compounds prove to be highly active 
against clinically relevant Gram-negative and Gram-positive bacteria. In vitro and in vivo tests show 
the low toxicity of the compounds. Their antimicrobial activity against resistant and multidrug-
resistant bacteria is at the membrane level, although other targets may also be involved depending 
on the bacterial strain.
Infectious diseases are the second most common cause of death worldwide. While multidrug resist-
ance is observed in both Gram-positive and Gram-negative bacteria, two thirds of deaths are due to 
infection by Gram-negative bacteria1. Antibiotic-resistant bacteria have emerged as a major problem, 
especially for hospital-acquired infections, and the economic cost of multi-drug-resistant bacterial infec-
tions is immense. Of the 2 million people infected in the EU every year, some 175,000 (about 9%) die2. 
The Centre for Disease Control and Prevention (CDC) in Atlanta similarly estimates that in the USA, 
more than 2 million patients acquire antibiotic-resistant infections every year, of who at least 23,000 
die3. Currently, more people die in USA of methicillin‐resistant Staphylococcus aureus than of AIDS. 
Meanwhile, the development of effective antibiotics has slowed down. Only seven new antibiotics were 
approved by the FDA from 2003 to 2012 (only two new classes since 1998), most of them effective against 
Gram-positive bacteria4–12.
All this makes it clear that there is an urgent need to develop new antibiotics against bacteria that are 
prone to acquire resistance to the antibiotics currently in use. The Infectious Disease Society of America 
has issued a proposal to develop new antibacterial drugs by 2020 against “ESKAPE” bacteria, which 
include the Gram-negative Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae 
(i.e. Escherichia coli and Klebsiella pneumoniae), and the Gram-positive Enterococcus faecium and 
Staphylococcus aureus13. Furthermore, in 2012 the Innovative Medicines Initiative (IMI, co-funded by the 
European Union and EFPIA pharmaceutical companies) launched a €223 million New Drugs 4 Bad Bugs 
(ND4BB) program to spur the development of new antibiotics5,14,15. A major goal in antimicrobial drug 
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discovery is the generation of new compounds capable of selectively killing resistant pathogens, possibly 
by novel mechanisms of action that could impede the development of resistance in the microorganisms.
Natural antimicrobial peptides (AMPs) have become a new class of antibiotics used to treat resist-
ant bacterial infections including septic-shock16–28. They are a unique and diverse group of molecules 
produced by a variety of plant, invertebrate and higher animal species. Despite the diversity of their 
structures, most of them share common features, such as an amphipathic character and several charged 
residues. Similar structural features have been successfully induced in biodegradable antimicrobial pol-
ymers and nanostructures29. It has been claimed that the use of antibacterial agents that disrupt the 
membrane bilayer is a promising alternative approach to regular antibiotic action, since such agents have 
the additional advantage of being active against dormant bacteria (with slow or even no growth). Such 
metabolically inactive organisms can survive high concentrations of classic antibiotics, and extended 
treatment is therefore required for drug efficacy30.
Altogether it is evident that there is a clear unmet medical need in the field of infectious diseases 
and new, broad-spectrum and safer antibiotics are urgently required, particularly to fight extended and 
pandrug-resistant bacteria.
Results and Discussion
Design of compounds. Inspired by natural cyclic AMPs, particularly polymyxins, we embarked on a 
project to design cyclic lipopeptides with a chemically accessible scaffold structure, high activity and low 
toxicity. Since polymyxins are selective for Gram-negative bacteria, we also wished to explore features 
that could lead to potential activity against Gram-positive bacteria, particularly S. aureus.
From the structural point of view, polymyxin B (PxB) and polymyxin E (PxE, colistin) are lipopeptide 
macrolactams with a tail-to-side-chain amide bond (Fig. 1), while the fatty acid moiety typically contains 
a stereocenter. Although the preparation of natural polymyxins via different synthetic routes has been 
reported, these two structural features would presumably complicate the synthesis of multiple analogs 
and the large-scale preparation of multigram (or kg) amounts for future clinical and therapeutic appli-
cations. One of our first objectives was therefore to reduce the complexity of the macrocyclic backbone 
scaffold. A plausible approach would consist of substituting the amide bond by an isosteric and more 
chemically accessible link, such as a disulfide bond. Disulfides are also chemical linkages present in some 
cyclic peptide drugs, as discussed below. Loop structures linked by disulfide bonds are not uncommon 
in cyclic AMPs. Examples are found in bactenicin (from cattle), lactoferricin, brevinins (from the frog 
Figure 1. General structure of the cyclolipopeptide analogs (upper left, analog 1, see Table 1). The structural 
and chemical features discussed for the design of the analogs are highlighted. Natural polymyxin B is 
shown below. The structure of lanreotide (right), a commercially available disulfide cyclic peptide having 
two D-amino acids is shown for comparison. Lanreotide is used for the treatment of acromegaly and 
neuroendocrine tumours and some 100-200 Kg are produced every year worldwide.
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Rana brevipoda), ranalexin (from the frog Rana catesbeiana), esculentin (from the frog Rana esculenta) 
and pipinin (from the frog Rana pipiens). The similarity between the macrocyclic heptapeptide structure 
in ranalexin and polymyxin was already noted by Zasloff31.
Similarly, Porro et al. described all-L-amino acid polymyxin-derived cyclic heptapeptides capable of 
binding to lipid-A with high affinity and detoxifying bacterial lipopolysaccharide (LPS) in vitro, but 
which showed no antibiotic activity32.
Altogether, this background and these structural data support the theoretical feasibility of substituting 
the tail-to-side-chain amide bond by a disulfide bond. This modification would imply changing both 
Thr10 and Dab4 for cysteines. In addition, the C-terminal cysteine would need to be derivatized as a 
carboxamide to mimic the neutral hydroxyethyl threonine moiety being substituted, as shown in Fig. 1.
Another important issue is the stereochemistry of the cysteines. Cysteine in position 4 should have 
the l configuration, whereas cysteine 10 ought to have the opposite d configuration, since the latter 
residue would be cyclized by means of the thiol side chain rather than from the backbone as in natural 
polymyxin (the Thr10 carboxy group). In the generation of analogues, both configurations were tested, 
but the most active compounds were those with a terminal D-cysteine amide.
Stability in the biological milieu was also taken into account when considering the design of com-
pounds. Peptide drugs such as octreotide, lanreotide or vapreotide (analogs of somatostatin that consist 
of a disulfide cyclic octapeptide) were analyzed. Somatostatin is a natural hormone with a half-life of 
2–3 minutes which is quickly proteolyzed when administered in vivo. However, lanreotide and vapreotide 
are much more stable to metabolic degradation (half-lives of around 2–3 hours) mainly due to the pres-
ence of D-amino acids (D-naphthylalanine/D-phenylalanine, and D-tryptophan). This suggests that the 
presence of D-amino acids in our disulfide-cyclized lipopeptides could improve their proteolytic stability 
and hence increase their half-lives and bioavailability. The most promising compounds we found in this 
respect contained two D-amino acids (the naturally occurring D-Phe6 and D-Cys10), as discussed below.
The disulfide bond may have additional potential as a pharmacological tool. On the one hand, it is 
known that PxB tends to accumulate over long periods (at least 48 h) in kidneys long after iv admin-
istration and after it has become barely detectable in serum (i.e., more than 30 times the serum con-
centration after 6 h). This suggests a selective uptake process in renal cells. Moreover, accumulation of 
PxB in kidneys could be correlated to its nephrotoxicity potential33,34. On the other hand, if this is the 
case with our novel PxB analogs, eventual uptake by renal cells would presumably reduce the disulfide 
and open up the peptide cycle due to the reducing intracellular environment (reduced glutathione and 
oxidorreductases) and thus facilitate the proteolysis of the linear sequence35–37. Hence, the disulfide link 
may provide PxB analogs with sufficient stability to reach the infectious target in vivo, whereas upon 
eventual accumulation and uptake by renal cells, reduction and subsequent decyclization would facilitate 
peptide proteolysis and potentially lower renal toxicity.
Finally, to further simplify the lipopeptide structure, the branched natural fatty acid tail was substi-
tuted by a linear one (nonanoic, decanoic or dodecanoic acids).
With all these structural features and a clear scaffold established, analogs were generated (Table  1). 
The initial idea consisted of introducing conservative substitutions of amino acids that are common in 
broad-spectrum AMPs, such as arginine, lysine and tryptophan. Hence, basic L-α ,γ -diaminobutyric acid 
(Dab) residues were substituted by arginine, lysine, and also by ornithine or L-α ,γ -diaminopropionic 
acid (Dap) residues (see also Supplementary Table S1). In particular, it was hypothesized that the guan-
idine group in arginine would increase electrostatic interactions with the phosphate groups of LPS due 
to its ambident nature and thus render higher antibiotic activity. Hydrophobic 6–7 positions were probed 
with other aromatic or aliphatic amino acids (D-tryptophan, norleucine and D-leucine). Threonine was 
maintained in position 2, as this amino acid seems to be involved in hydrogen bonding with the amide 
nitrogen of Dab3 and the carbonyl of Dab4, thereby helping polymyxin to bend and adopt a conformation 
necessary to interact with LPS38.
Preparation and Evaluation of compounds. A first series of lipopeptides were synthesized by 
solid-phase chemical methods, cyclized at high dilution, purified (> 95%) and their minimal inhibitory 
concentration (MIC) evaluated. A selection of the most representative compounds is shown in Table 1 
(the other MIC values are in the Supplementary Table S1).
The first compound (1) consisted of the canonical application of our design principles to PxB. Thr10 
and Dab4 were substituted by cysteines and the natural fatty acid was changed to the linear nonanoic 
acid. Moderate activity was obtained against representative Gram-negative bacteria, such as P. aeruginosa 
and E. coli (MIC 8 and 4 μ g/mL, respectively). However, no activity was observed against Gram-positive 
S. aureus.
Addition of a single arginine did not improve this activity (analogs 2, 3 and 4). However, the intro-
duction of two or three arginines (analogs 5, 6 and 8) conferred moderate activity against S. aureus. 
Additional arginines had a detrimental effect, particularly against Gram-negative bacteria (analogs 10 
and 12). Furthermore, cytotoxicity was found to increase with the number of arginines (Table 2). Hence, 
analogs with few (1 or 2 arginines) or no arginines were preferable from this point of view.
The introduction of D-cysteinamide at the C-terminal (13) also had positive effects, as activity against 
E. coli and P. aeruginosa was maintained, while the spectrum of activity apparently broadened towards 
S. aureus. We also explored the use of longer fatty acid moieties, (36, 37) such as the decanoic acid 
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(the fatty acid present in daptomycin) and dodecanoic acid, mainly to try to improve activity against 
Gram-positive bacteria, as described previously in the literature38–40.
Leucine, which contains a branched isobutyl side chain, was substituted with an isomeric norleucine, 
which has a linear butyl side chain. The idea behind this substitution was to introduce a more flexible 
and longer C4 hydrocarbon side chain, as in the linear fatty acid of the N-terminus, but essentially main-
taining the lipophilicity of the residue.
Finally, when all these structural elements (decanoic/dodecanoic fatty acid, D-cysteinamide, norleu-
cine, few arginines, or better, all-Dab analogs) were added together, activity against Gram-negative bac-
teria reached MIC values comparable to those of natural PxB (analogs 38 and 39). Furthermore, activity 
against S. aureus reached values of 2-4 μ g/mL. It is worth noting that both peptides 38 and 39 shared 
the same peptide sequence, with only a difference in the length of the N-terminal fatty acid.
To further explore the extent of the activity against Gram-positive bacteria of the most active 
sequence (all-Dab, Nle7, DCys10), its MIC values were evaluated in strains of S. aureus and Enterococcus 
faecalis, including clinical isolates and laboratory-derived strains at Cubist Pharmaceuticals (Lexington, 
MA). Lipopeptide 39 was chosen for this, as it is known that long fatty acids tend to favor activity 
against Gram-positive bacteria in polymyxin analogs38–41. The MIC values obtained demonstrated that 
its antibiotic activity was similar to that of daptomycin and vancomycin (see Table 3). In summary, new 
broad-spectrum antimicrobial lipopeptides were achieved.
N° Peptide sequence S. aureus P. aeruginosa E. coli
1 nonanoyl-Dab-Thr-Dab-Cys-Dab-Phe-Leu-Dab-Dab-Cys > 32 8 4
2 nonanoyl-Arg-Thr-Dab-Cys-Dab-Phe-Leu-Dab-Dab-Cys > 32 8 8
3 nonanoyl-Dab-Thr-Arg-Cys-Dab-Phe-Leu-Dab-Dab-Cys > 32 4 8
4 nonanoyl-Dab-Thr-Dab-Cys-Dab-Phe-Leu-Arg-Dab-Cys > 32 2 - 4 8
5 nonanoyl-Arg-Thr-Dab-Cys-Dab-Phe-Leu-Arg-Dab-Cys 32 16 8
6 nonanoyl-Dab-Thr-Arg-Cys-Dab-Phe-Leu-Arg-Dab-Cys 16 8 8
8 nonanoyl-Arg-Thr-Arg-Cys-Dab-Phe-Leu-Arg-Dab-Cys 8 8 4
10 nonanoyl-Arg-Thr-Arg-Cys-Dab-Phe-Leu-Arg-Arg-Cys 32 16 32
12 nonanoyl-Arg-Thr-Arg-Cys-Arg-Phe-Leu-Arg-Arg-Cys 8 16 - 32 8 - 16
13 nonanoyl-Arg-Thr-Dab-Cys-Dab-Phe-Leu-Arg-Dab-Cys 16 8 4
36 decanoyl-Arg-Thr-Dab-Cys-Dab-Phe-Leu-Arg-Dab-Cys 16 8 8
37 decanoyl -Dab-Thr-Dab-Cys-Dab-Phe-Leu-Dab-Dab-Cys 8 4 2
38 decanoyl -Dab-Thr-Dab-Cys-Dab-Phe-Nle-Dab-Dab-Cys 4 1 2
39 dodecanoyl-Dab-Thr-Dab-Cys-Dab-Phe-Nle-Dab-Dab-Cys 2 1 4
Control Polymyxin B (control Gram-negative bacteria) > 32 2 1
Control Daptomycin (control Gram-positive bacteria) 1 - -
Control Vancomycin (control Gram-positive bacteria) 1 - -
Table 1.  Selection of the most representative cyclic lipopeptides and their activities (MIC). The sequence is 
displayed in three-letter code. Amino acids substituted with respect to the parent sequence (1) are marked 
in red. D-amino acids are denoted in italics (Phe or Cys). Antimicrobial activities (MIC, μ g/mL) for Gram-
negative (P. aeruginosa and E. coli) and Gram-positive (S. aureus) are listed. Cysteine residues form a 
disulfide bond. The C-terminal amino acid is derivatised as an amide (i. e. cysteine amide). The MIC of the 
rest of compounds may be found in the Supplementary Table S1.
Analog 5 (2 Arg) Analog 8 (3 Arg) Analog 12 (5 Arg)
hDF 534 461 164
MDCK 548 472 190
PC12 629 595 225
Table 2.  In vitro cytotoxicity of some lipopeptide analogs. IC50 (μ g/mL) values of analogs 5, 8, and 12 
having 2, 3 and 5 arginines, respectively, are shown. Cell cultures of human dermic fibroblasts (hDF), 
Madine-Darby canine kidney cells (MDCK, renal model) and PC12 (treated with NGF, neuronal model) 
have been used (see Supplementary Table S2 for statistics).
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Activity against resistant and multi-drug-resistant Gram-negative bacteria. To study the 
potential activity of the most active sequences (compounds 38 and 39), MIC assays were carried out 
with clinical isolates from resistant/multi-drug-resistant Gram-negative bacteria. Strains of E. coli and 
P. aeruginosa with resistance to quinolones and carbapenems as well as multi-drug-resistant bacteria 
were tested. The MIC results showed that the compounds were even more active against the selected 
strains than against regular ATCC bacteria strains, with many MIC values in the submicromolar range 
(0.5 μ g/mL), which are comparable to those of natural PxB and colistin. It is worth mentioning that an 
E. coli strain containing the New Delhi metallo-beta-lactamase gene (NDM-1) isolated from a traveler 
to India42, which is resistant to β -lactamic antibiotics (penicillins, cephalosporins, monobactams, and 
carbapenems), aminoglycosides, and quinolones, showed MIC values for the new compounds of 0.5 μ g/
mL (see Table 4).
In vivo acute toxicity test. An in vivo acute toxicity test was performed on CD-1 mice. The lethal 
dose (LD50) was determined according to the up-and-down procedure. Compound 38 was administered 
subcutaneously at designated doses (100, 200 and 400 mg/kg). Mice treated with 100 and 200 mg/kg of 
compound 38 survived with no signs of toxicity; whereas mice administered 400 mg/kg died. After 14 
days, necropsy of the three surviving mice (dosed at 200 mg/kg) showed no signs of pathology in vital 
organs. LD50 was determined using the maximum likelihood method and a value of 283 mg/kg was 
obtained. This value is significantly higher (almost 5 times) than the LD50 reported for subcutaneous 
administration of PxB (59.5 mg/kg). Hence, analog 38 has a significantly lower toxicity than natural PxB, 
according to this toxicity test.
Flow cytometry. The mechanism of action at the membrane level of our best candidate was studied 
using flow cytometry. To assess membrane permeability, a propidium iodide (PI) probe was used43,44. 
The fluorescence conferred by this probe is generally associated with cells that have lost their membrane 
integrity. The effect on membrane potential was evaluated with bis-(1,3-dibutylbarbituric acid) trime-
thine oxonol (BOX). Membrane depolarization leads to the incorporation of this anionic dye into the cell 
where it binds to lipid-rich intracellular compounds, resulting in an increase in fluorescence.
E. coli and S. aureus were used as models for Gram-negative and Gram-positive bacteria, respectively. 
PxB is known to target the membrane of Gram-negative bacteria, and was used as a control in E. coli. As 
S. aureus E. faecalis
MS 
ATTC 
29213
DR, MS 
SAU.278
MR 
ATTC 
43300
MR 
SAU.1118
DR, MR 
SAU.1616
Wild type 
ATTC 
29212
39 1 2 1 1 8 2–4
daptomycin 0.5 8 0.5 0.5 16 2–4
vancomycin 0.5-1 2 2 0.5 2 2
Table 3. Activity (MIC, μ g/mL) of synthetic lipopeptide 39, daptomycin and vancomycin against Gram-
positive S. aureus and E. faecalis, including clinical isolates and laboratory-derived daptomycin (DR) 
resistant strains from Cubist Pharmaceuticals (MS, methicillin sensitive; MR, methicillin resistant).
Strain Resistance profile 38 39 PxE PxB
E. coli MAC 21a nalidixic acid, cotrimoxazole and ampicillin 0.5 1 0.5 0.25
E. coli VAL 10 nalidixic acid, cotrimoxazole and ampicillin 0.5 0.5 0.5 0.25
E. coli VAL 5 nalidixic acid 0.5 0.5 0.25 0.25
E. coli NDM-1 highly-resistanta 0.5 0.5 0.5 0.5
P. aeruginosa 40b imipenem (MIC 32 mg/L) 4 2 1 2
P. aeruginosa 38a ceftazidime, ciprofloxacin, imipenem, piperacillin-tazobactam 0.5 1 1 1
Table 4.  Activity (MIC, μ g/mL) of lipopeptides 38 and 39 against resistant and multidrug-resistant Gram-
negative E. coli and P. aeruginosa strains. MIC of colistin (polymyxin E) and polymyxin B are shown for 
comparison. aResistance profile (MIC): Amoxicillin 256 mg/L; Amoxicillin clavulanate 32 mg/L; Piperacillin/
tazobactam 256 mg/L; Cefoxitin 256 mg/L; Cefotaxime 256 mg/L; Ceftazidime 256 mg/L; Cefepime 256 mg/L; 
Imipenem 8 mg/L; Meropenem 16 mg/L; Doripenem 6 mg/L; Ertapenem 24 mg/L; Aztreonam 256 mg/L; 
Gentamicin 8 mg/L; Amikacin 32 mg/L, Tobramycin 8 mg/L; Ciprofloxacin 32 mg/L (see42).
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expected, the flow cytometric analysis showed that PxB induces high levels of permeabilization quickly 
(around 70% in 120 min, see Table  5) and to a lesser extent, depolarization. However, depolarization 
seems to happen at the initial stages, since samples taken after 5 minutes of incubation showed only 11% 
permeability compared to around 45% depolarization (see supplementary Table S3 and supplementary 
Figure S4). These results suggest that the first effect of the presence of PxB in the medium is the col-
lapse of the membrane potential (depolarization) which is followed by insertion and disruption of the 
cytoplasmic membrane (permeability).
In order to study the extent to which the dye is inserted into the bacteria, and thus characterize the 
insertion of PxB, a control experiment was also carried out with PxB nonapeptide (PxBN), a delipidated 
and truncated PxB derivative. PxBN is devoid of antibiotic activity but retains the capacity to bind to 
LPS and disorganize the outer membrane of Gram-negative bacteria. We hypothesized that in the case 
of bacteria treated with PxBN, PI would not cross the bacterial cytoplasmic membrane, as PxBN is only 
capable of disrupting the outer membrane. Our results confirmed this hypothesis, since no depolari-
zation or permeabilization was detected (only a 3%-6% background) after 60 minutes of incubation at 
5 μ g/mL (10 times the MIC of PxB). A final control of staining consisting of bacteria cells subjected to a 
thermal shock (30 min, 70 °C) was also performed.
When E. coli (see Table 5 and supplementary Figure S4) was incubated with peptide 38, a progres-
sive, time-dependent permeabilization took place, but more slowly (7% in 30 min; 43% in 120 min) than 
with natural PxB. However, dissipation of the membrane potential occurred very quickly: around 50% 
in 30 min. According to the results, it seems that peptide 38 causes small breaches of the permeability 
barrier of the cytoplasmic membrane (or disruption of its proper functioning) resulting in rapid mem-
brane depolarization. Membrane permeabilization appears after longer incubation times. Viability counts 
measured in parallel indicated that there is a good correlation between changes in membrane integrity 
and cell death. However, for S. aureus, no significant effect was observed on membrane potential (4%) or 
permeability (4%); whereas cell viability measured in parallel showed an 85% reduction. The differences 
between the results obtained by bacterial count and the PI staining indicate the presence of cells that 
maintained membrane integrity but were not able to grow, suggesting that the membrane is not the only 
target of compound 38 in S. aureus. Altogether, these results seem to suggest that different mechanisms 
of action may be involved in the activity of this lipopeptide, depending on the nature of the microor-
ganism studied. The difference observed here between S. aureus and E. coli might be due to differences 
in envelope structure and composition. The cell walls of Gram-positive bacteria contain a peptidoglycan 
layer that is thicker than that in the cell walls of Gram-negative bacteria, providing the former bacteria 
with increased rigidity and this could be why no lysis of the membrane was barely observed in S. aureus, 
although other effects were seen by electron microscopy, as explained below. Another explanation could 
be that the lipopeptide also targets intracellular receptors, either a protein, nucleic acids or other poten-
tial targets, as has been observed with other AMPs18,25. PxB has been identified as an inhibitor of alterna-
tive NADH dehydrogenase45,46 and malate:quinone oxidoreductase in the Gram-positive Mycobacterium 
smegmatis (IC50 1.6 and 4.3 μ g/mL, respectively). Kinetic analysis of inhibition by PxB has shown that 
the primary site of action is the quinone-binding site45.
E. coli S. aureus
% of stained 
cells
% 
viability 
reduction
% of stained 
cells
% 
viability 
reduction
Sample
Concentration 
(μg/mL)
Incubation 
time (min) PI BOX PI BOX
- 30 3 5 - 1 5 -
Control - 60 3 5 - 1 5 -
- 120 2 4 - 2 5 -
0.5 30 68 13 65 - - -
PxB 0.5 60 57 23 87 - - -
0.5 120 71 17 98 - - -
PxBN
5 30 10 5 0 - - -
5 60 3 6 5 - - -
4 30 7 47 20 2 1 15
#38 4 60 23 50 60 3 1 60
4 120 43 47 85 4 4 85
70 °C - 30 80 11 100 35 25 100
Table 5.  Flow cytometry analysis and reduction of viability (obtained by plate count) of E. coli and S. 
aureus treated with PxB, PxBN and analog 38.
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Transmission Electron Microscopy. The effects of the lipopeptides studied on the cell morphology 
of E. coli and S. aureus were also observed via transmission electron microscopy (TEM). Untreated E. 
coli cells in a standard tryptone water medium showed a normal cell shape with an undamaged structure 
of the inner membrane and an intact outer membrane (data not shown). When E. coli was incubated 
with PxB as a control (120 min at 0.5 μ g/mL: MIC), numerous protrusions were observed at the outer 
cell membrane and even some completely lysed membranes (Fig.  2a, b; solid arrow). Similarly, analog 
38 induced notable modifications of the bacterial cell membranes, with different effects observed. The 
TEM images show abnormal membrane septation and the formation of blebs on the bacterial surface, 
similar to those induced by PxB (Fig. 2c, solid arrow). In addition, numerous intracellular membranous 
structures were observed in the polar cell regions together with a collapsed cytoplasm (Fig. 2d, dashed 
arrow). Moreover, the periplasmic space was highly swollen, probably due to the leakage of cellular 
material from the cytoplasm.
Treatment of S. aureus with lipopeptide 38 (at 4 μ g/mL) induced numerous double-layered spherical 
mesosome-like structures as well as spherical non-membrane-enclosed bodies with an electron density 
similar to that of the septal cell wall layer (Fig.  3a, b). In addition, a retraction of the cytoplasm was 
observed. Mesosomes are intracytoplasmic membrane inclusions that indicate cytoplasmic membrane 
alteration caused by antibiotic activity. Since the cytoplasmic membrane is instrumental in cell wall 
synthesis and turnover, perturbation of this membrane may also affect cell wall integrity and autolysin 
regulation. Accordingly, the very fact that mesosome-like structures were seen in most treated cells indi-
cates cytoplasmic membrane alteration and (possibly) uncoupling of the synthesis and turnover of cell 
wall polymers47. It has also been hypothesized that the formation of mesosomes in bacteria responds to 
a defensive mechanism to protect the bacteria from antibiotic assault. In fact, these invaginations have 
been observed after exposure to antibiotics as different as amikacin, gentamicin, ciprofloxacin, vanco-
mycin, or oxacillin48.
Conclusions
We designed and synthesized a series of cyclic lipopeptides based on a versatile and chemically acces-
sible scaffold. The most active analogs were shown to have excellent antimicrobial activity against both 
Gram-negative (P. aeruginosa and E. coli) and Gram-positive (S. aureus and E. faecalis) clinically relevant 
bacteria. Their antimicrobial activity is at the membrane level although other targets may also be involved 
depending on the bacterial strain. Moreover, the most active sequence showed low toxicity in vivo, thus 
suggesting that a satisfactory therapeutic window could be achieved. Altogether, these new chemical 
Figure 2. TEM micrographs of treated E. coli. a,b, after treatment with PxB (0.5 μ g/mL) numerous 
protrusions (solid arrow) from the cell surface are observed. c,d, after treatment with lipopeptide 38 (2 μ g/
mL) the effect is diverse, showing numerous membranous structures, protrusions of the membrane similar 
to PxB (dashed arrow).
www.nature.com/scientificreports/
8Scientific RepoRts | 5:10558 | DOi: 10.1038/srep10558
entities are suitable compounds for hit-to-lead development. Synthesis of these novel cyclic lipopeptides 
can be readily scaled up for commercial use, including treatment of various infectious diseases caused 
by multi-drug-resistant bacteria.
Experimental Part
Peptide synthesis. Peptide synthesis was performed following standard Fmoc/tBu procedures on 
Rink derivatised 4-methylbenzhydryl amine polystyrene resins, as described elsewhere28,49,50. Cyclization 
of peptides was carried out in DMSO:water (5:95) or ammonium bicarbonate buffer (100 mM, pH = 10) 
for 24–48 hours and monitored by analytical HPLC. The homogeneity was assessed by analytical HPLC 
using H2O-MeCN-TFA as eluants. Peptides were purified by semi-preparative HPLC to > 95% and were 
characterized by analytical HPLC and MALDI-TOF or ESI mass spectrometries (see characterization of 
analogs 38 and 39 in the Supplementary Figure S5).
In vitro microbiological activity in ATCC and resistant bacteria (MIC determination). MICs 
were measured after 18–20 h of incubation in sterile 96-well plates (Corning Costar 3598 microtiter 
plates) in Mueller Hinton Broth (MHB) culture medium, (Difco, USA), according to well known in vitro 
protocols51. Bacterial strains in Table 1 were: P. aeruginosa ATTC 9027, E. coli ATTC 8739, S. aureus 
ATTC 6538, and E. faecalis ATTC 29212. MICs shown in table 4 were performed by Mary Conrad at 
Cubist Pharmaceuticals (Lexington, MA) in non-binding surface plates.
In vitro cytotoxicity. Cell viability assays were performed using the tetrazolium dye WST1 (similar 
to MTT) on human dermal fibroblasts (3T3 hDF), MDCK (renal model, Madin-Darby canine kidney 
cells) and PC12 (NGF treated; neuronal model) cell lines and followed standard protocols52. Briefly, cells 
were seeded into 96-well plates, after incubation for 24 h, the medium was replaced with fresh cell cul-
ture medium containing the products (range 0-1.2 mg/mL). Negative and positive controls consisted of 
plates in the absence of the test compound and plates with sodium dodecyl sulfate (0.02% w/v), respec-
tively. Cell viability was assayed with the tetrazolium salt (4-[3-(4- iodophenyl)-2-(4-nitrophenyl)-2H-5
-tetrazolio]-1,3-benzene disulfonate) (WST-1). The relative WST-1 absorbance was recorded at 450 nm.
The products at concentrations ranging from 0 to 1.2 mg/mL were tested (triplicate) and in two inde-
pendent experiments. The statistical analysis of the data was performed by using non-linear regression 
(curve-fit) and the model used agreed with the four parameter logistic model (4PL), also called the 
Hill-Slope model (sigmoid model), with the following equation:
y bot top bot
x IC1 slope50
= + ( − )
+ ( / )
where y is the percent activity and x is the corresponding concentration. The quantities determined 
where the point estimate IC50 (Half maximal (50%) inhibitory concentration (IC) of a substance, see 
Table II), the corresponding 95% confidence interval and R2 (measures the goodness of fit) are shown 
in the Supplementary Table S2.
In vivo toxicity studies. The evaluation of acute toxicity was conducted based on OECD 425 (Acute 
Oral Toxicity – Up-and-Down-Procedure (UDP) March 2006). The procedure was evaluated and accepted 
by the Ethical Committee of Experimental Animals of the University of Barcelona.
The main test consists of a single ordered dose progression in which animals are dosed, one at a time, 
at a minimum of 24-hour intervals.
Figure 3. TEM micrographs of treated S. aureus. a,b, after treatment with lipopeptide 38 (4 μ g/mL), 
mesosome-like structures and defects on the cell wall can be observed.
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Compound 38 was dissolved in PBS (pH 7.4), and administered subcutaneously to CD-1 mice at 
selected doses (100, 200 and 400 mg/kg). Since 5 reversals occurred in 6 consecutive animals tested 
between the 200 mg/Kg dose (the 3 animals, survived), and the 400 mg/Kg dose (the 3 animals died) the 
test was stopped.
Mortality was monitored for 14 days post-treatment, and LD50 was determined using the maximum 
likelihood method.
Flow Cytometry. Bacteria, growth conditions and antimicrobial treatment. An overnight culture (12 
to 16 h) of S. aureus (ATCC 29213) or E. coli (ATCC 25922) in Tryptic Soy Broth (TSB) was grown at 
37 °C and 400 μ L were added in 50 mL of tryptone water (∼ 107 bacteria/mL). The bacterial suspension 
was split into aliquots of 4-5 mL and treated with the peptides (at the MIC) for different incubation 
times at room temperature. Cells were collected by centrifugation (10000 rpm, 20 min) and resuspended 
in 1 mL of filtered Ringer’s solution.
Staining procedure. A stock solution of propidium iodide (PI, 1 mg/mL, Molecular Probes) and 
bis-(1,3-dibutylbarbituric acid) trimethine oxonol (BOX, 250 μ M, Sigma Aldrich) was prepared in dis-
tilled water. Portions (10 μ L and 2 μ L, respectively) were added to aliquots of cells (100 μ L of each sample 
in 1 mL of Ringer’s solution) to give a final concentration of 10 μ g/mL of PI and 0.5 μ M for BOX.
Analysis. Flow cytometric measurements were performed on a Gallios multi-colour flow cytometer 
instrument (Beckman Coulter, Inc, Fullerton, CA) set up with the 3-lasers 10 colors standard config-
uration. Excitation was done using a blue (488 nm) laser. Forward scatter (FS), side scatter (SS), green 
fluorescence (525/40 nm) from BOX and red fluorescence (620/30 nm) emitted by PI were collected 
using logarithmic scales. FS was used as the discriminating parameter. The single-cell bacterial popu-
lation was selected on a forward-side scatter plot. Fluorescence was presented in a dot plot of BOX vs. 
PI. Three regions were defined on this graph according to the controls: depolarized, permeabilized and 
non-affected cells. Control cells (non-stained and single stained populations) were used to define these 
regions. 25,000 cells defined according to their scatter parameters were counted in each sample.
Transmission Electron microscopy (TEM). Bacteria, growth conditions and antimicrobial treat-
ment. An overnight culture (12 to 16 h) of S. aureus (ATCC 29213) or E. coli (ATCC 25922) in Tryptic 
Soy Broth (TSB) was grown at 37 °C and 500 μ L were added in 50 mL of tryptone water (∼ 108 bacteria/
mL). The bacterial suspension was split into aliquots of 10 mL and treated with the peptides (at the MIC) 
for 120 minutes at room temperature. Cells were collected by centrifugation (10000 rpm, 20 min).
Transmission Electron microscopy preparation and observation. Samples were fixed with 2.5% gluta-
raldehyde in phosphate buffer for 2 h at 4 °C, then washed with the same buffer and post fixed with 
1% osmium tetroxide in buffer containing 0.8% potassium ferricyanide at 4 °C. The samples were then 
dehydrated for 1 hour in acetone and infiltrated in a gradded series of Epon resin (Ted Pella Inc., USA) 
during 2 days, and finally embedded in fresh Epon resin and polymerised at 60 °C during 48 hours.
Ultrathin sections were obtained using a Leica Ultracut UCT ultramicrotome (Leica, Vienna) and 
mounted on Formvar-coated copper grids. Sections were stained with 2% aqueous uranyl acetate and 
lead citrate and examined in a JEM-1010 electron microscope (Jeol, Japan).
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